通过PI3K/AKT和Hippo通路调节预防化疗诱导的卵巢损伤
Negin Zatalian1,2, Azam Dalman3, Hamid Gourabi4
1Department of Molecular Cell Biology-Genetics, Faculty of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
概括
化疗可能会损害卵巢储备,影响生育能力. 用特定药物向PI3K/AKT和Hippo通路可能会在癌症治疗期间保持卵巢功能和生育能力.
科学领域:
- 在瘤学瘤学.
- 生殖生物学 生殖生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症治疗,特别是化疗,可以提高生存率,但可以通过破坏卵巢储备而导致不孕症.
- 现有的生育保护方法对癌症患者有局限性.
- 化疗期间的卵巢损伤与PI3K/AKT和Hippo等分子通路有关.
研究的目的:
- 审查在化疗期间通过调节PI3K/AKT和Hippo通路来保持卵巢储备的药物.
- 确定治疗目标,以减轻化疗引起的卵巢毒性.
主要方法:
- 对研究影响PI3K/AKT和Hippo通路的药物进行系统审查.
- 分析与化学疗法药物 (如环胺和西斯) 一起使用的药物.
- 专注于涉及PI3K/AKT和/或Hippo通路调节的药物.
主要成果:
- 33种药物被确定为可能保护卵巢储备.
- 大多数研究的药物主要向PI3K/AKT通路.
- 有证据表明,这些途径对于化疗引起的卵巢损伤至关重要.
结论:
- 调节PI3K/AKT和Hippo通路,重点是PI3K/AKT,可以保护卵巢储备免受特定的化疗.
- 这种方法有可能在接受治疗的癌症患者中保持生育能力.
- 对这些途径的进一步调查可能会导致新的节育策略.
相关概念视频
Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...


